Clinical study of sarcomatoid renal cell carcinoma by 大庭, 康司郎 et al.
Title肉腫様腎細胞癌の臨床的検討
Author(s)大庭, 康司郎; 古賀, 成彦; 錦戸, 雅春; 宮田, 康好; 野口, 満;金武, 洋; 神田, 滋; 林, 徳真吉; 山田, 潤


















CLINICAL STUDY OF SARCOMATOID RENAL CELL CARCINOMA 
Kojiro OHBA， Shigehiko KOGA， Masaharu N回王IKIDO，
Yasuyoshi MIYATA， Mitsuru NOGUCHI and Hiroshi KANETAKE 
From the Department 01 Urology， Nagasaki University Graduate School 01 Biochemical Science 
Shigeru KANDA 
From the Department 01 Molecular Microbiology and lmmunology， Division 01 Endothelial 
Cell Biology， Nagasaki University Graduate School 01 Biochemical Science 
Tomayoshi HAYASHI 
From the Dψartment 01 Pathology， Nagasaki University Hospital 
Jun YAMADA 
From the Dψartment 01 Urology， Sasebo Kyosai Hospital 
131 
Patients with sarcomatoid renal cel carcinoma are rare and have poor survival. We evaluated 14 
patients who had renal cel carcinoma with a sarcomatoid component between 1982 and 2000. There 
were 9 men and 5 women with a median age of 59.5 years (range 32 to 77). Seven patients had a 
tumor on the right side and 7 on the left side. Thirteen patients had some symptoms and 11 had 
metastases at the initial visit. Most ofthem were stage T4 and high nuclear grade cancer and showed 
elevated acute phase reactants. There were 7 patients followed by interferon therapy， and the cause-
specific 5-year survival rate was less than 10%. We confirmed thatrenal cel carcinoma with a 
sarcomatoid component often showed local invasion， distant metastasis and poor prognosis. 
(Acta Urol. Jpn. 49: 131-133， 2003) 




















































(21.4%)， N2が l例 (7.1%)，MOは6例 (42.9%)， 
Mlが8例 (57.1%)であった.その結果，病期分類










1が6例 (46.2%)，grade 111が7例 (53.8%)，浸
潤増殖様式で、は INFα が3例 (33.1 %)， INFβ が9















83.2 mm/hr (2.0-170.0)で， 1例 (78.6%) が 30
mm/hr以上であった. CRPは平均 8.77mg/dl 
(0.16-18.20)で， 13例 (92.9%) が陽性であった
(Table 1). 
TNM分類については， Tlbが2例， T2が2例，
T3aが2例(各 14.3%) で， T4が8例 (57.1%) 
みられた.また NOが9例 (64.3%)，Nlが3例
果結
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Survival curve of patients with sarco幽
ma toid renal cell carcinoma (n = 14). 
The median survival of them was 10.6 
months (range 1.9 to 83.8) and 5 year暢
survival rate was 9.5 %. 
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acute phase reactantが上昇した rapidtypeの症例
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